PBAC's latest decision on Maraviroc: Deferred (2012). Considered for For the targeted treatment of all patients with CCR5-tropic HIV-1 infection, in combination with other antiretroviral agents. For initial treatment and continuing treatment of HIV-1 infection in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV-1 disease.
PBAC outcome
Deferred
2012
ICER (AUD/QALY)
$45k/QALY
$15k/QALY–$45k/QALY · across 2 submissions
Submissions
2
first 2008
Submissions
2
2008 → 2012
Eligible population
adult patients infected with only CCR5-tropic HIV-1 infection
Therapy area
Immunology
Line of therapy
First-line, Later-line
Evidence base
RCT, Registry
Primary endpoint
OS, PFS, DFS, ORR
Key trials
MERIT, MOTIVATE
Comparator
efavirenz
Economic model
CUA
ICER basis
Range aggregates 2 submissions (2008–2012) — not a single base case.
Submission history
Nov 2008: Not recommended · Authority Required — ICER $45k/QALY